Group 1 - JD Logistics and Faurecia (China) Investment Co., Ltd. signed a strategic cooperation agreement on April 25 [1] - The collaboration will focus on green low-carbon warehousing and transportation [1] - The partnership will also involve the JD Carbon Benefit SCEMP supply chain carbon management platform and a logistics carbon emission factor database [1]

一家来自中国的潮玩快闪店门前，蜂拥而至的消费者排起长队，不同肤色的年轻人唱起了《LABUBU之歌》。这是前不久发生在西班牙巴塞罗那市中心的 一幕。过去几年，如此神奇的情景已经在欧美、日韩、东南亚等多地上演。 如今，LABUBU、MOLLY、小野等潮玩形象，在全球拥有大量拥趸。而一手培育这些IP的泡泡玛特公司，是一家土生土长的北京企业。 情感共鸣让IP破圈 日前，记者来到位于朝阳区的泡泡玛特办公区。展示大厅里摆放着各种原创IP的潮玩，宛如一个童趣十足的乐园。"我们是一家潮流文化娱乐集团，IP运营 是核心。"泡泡玛特国际集团副总裁陈晓芸带记者穿梭在各种潮玩之间，"2024年，有13个IP营收过亿元，4个IP营收过10亿元。" CRYBABY就是头部IP之一。它是可爱的小哭包，蓝色泪水已经夺眶而出。不同系列的哭娃传递不同的情绪，有泪水代表坚持，有的象征快乐。虽然艺术家 是泰国籍，但哭娃却能触动不同文化背景的消费者，让大家找到情感共鸣。目前，泡泡玛特合作过的艺术家已经有近百位了。 一个爆款IP如何诞生？需要天时地利，更需要最好的艺术家和IP。公司创始人王宁将泡泡玛特比喻为"唱片公司"，全世界优秀的设计师、艺术家就是他 ...

Group 1 - The core viewpoint of the news is that Tianwo Technology (002564) reported a significant decline in revenue for the year 2024, with a total revenue of 2.464 billion yuan, representing a year-on-year decrease of 34.66% [2] - The company reported a net profit attributable to shareholders of 24.04 million yuan for 2024, while the net profit excluding non-recurring items showed a loss of 23.21 million yuan [2] - Tianwo Technology announced that it would not distribute cash dividends, issue bonus shares, or increase capital from reserves for the 2024 fiscal year [2] Group 2 - As of April 27, 2023, the company has received 108 notifications of litigation claims from minority shareholders, with a total amount involved of 13.84 million yuan [2] - The company has also received written claims or lawyer letters from 68 minority shareholders, totaling 13.73 million yuan in claims [2] - The company has made necessary accounting adjustments in accordance with relevant accounting standards regarding the litigation claims [2] Group 3 - In the first quarter of 2025, Tianwo Technology achieved a revenue of 605.2 million yuan, a year-on-year decrease of 4.07% [3][4] - The net profit attributable to shareholders for Q1 2025 was 18.39 million yuan, showing a year-on-year increase of 23.83% [3][4] - The company reported a net cash flow from operating activities of -22.74 million yuan, which improved by 88.95% compared to the previous year [4]

"水果第一股"重庆洪九果品股份有限公司（以下简称"洪九果品"）正经历一场前所未有的危机。近期， 其董事长邓洪九在内的6名核心高管因涉嫌骗取贷款、虚开增值税专用发票的事项被采取不同刑事强制 措施，其公司总部更是人去楼空，品牌标识被撕毁。 早在2024年3月，洪九果品股票就因2023年年报"难产"被停牌，后续持续爆出其财务或涉嫌造假，核数 师毕马威辞任，中汇安达接任但未有进展，而其财务危机不止于此，其现金流多年为负，截至2023年上 半年，借债高达27亿元。值得关注的是，截至目前，其停牌至今已超过10个月，距离港交所强制退市仅 剩不到6个月时间，业内认为，洪九果品若不能及时做出相应举措，将面临退市危机。 多位高管被采取刑事强制措施 近期公告披露，洪九果品董事长邓洪九、董事彭何、董事江宗英、董事杨俊文、董事谭波、监事会主席 余利霞目前均已被采取不同刑事强制措施，原因与重庆市两江新区公安分局就涉嫌骗取贷款及虚开增值 税专用发票的事项进行立案侦查相关。 同时，因为该立案侦查事件，自今年1月6日起，洪九果品一处主要办公地址被公安机关限制人员出入， 公司无法正常办公。洪九果品进一步指出，公司对该事件了解到的信息有限，该事件 ...

李后强 据说，著名学者张维迎教授曾讲到，传统文化行业是骗子云集之地，尤其是武术界、中医药界、国学 界、书法国画界。这是不是张教授讲的，我没有求证。至少，这种现象是局部存在的。其实，在中 国"酒文化""茶文化"界，骗子也不少。到目前为止，我们对中国白酒的认识都是停留在表面，根本没有 看清本质，而"酒文化"的骗子又大行其道，歪理邪说深得人心。因此，我认为中国白酒界如果不立刻清 醒，仍然处于"醉态"，那么苦日子还在后面，大批酒企会因骗子引导而自取灭亡。这就是残酷的现实与 未来！清醒的路径之一，就是从"牛顿思维"转向"量子思维"。 一、当前中国白酒的困境：牛顿思维的失效 中国白酒行业正经历结构性危机。2024年数据显示，白酒消费市场进入"量价双降"周期，高端酒价格倒 挂率超60%，次高端产品流通价跌破出厂价，经销商库存周转天数普遍超过200天。传统营销模式依 赖"渠道蓄水"和"规模化扩张"，通过压货完成业绩目标，但如今渠道库存积压、经销商毛利率压缩至不 足8%，形成"降价－贬值－滞销"的恶性循环。这种困境的根源在于牛顿思维的失效——将市场视为线 性、确定、可预测的系统。传统白酒企业以"静态数据"为决策依据，试图通过价 ...

*ST嘉寓（300117）收到股票终止上市决定，*ST龙津（002750）收到终止上市事先告知书。 4月25日晚，深交所发布了《关于嘉寓控股股份公司股票终止上市的公告》，决定终止*ST嘉寓公司股票上市。 同日，*ST龙津发布公告称，收到深交所《终止上市事先告知书》，由于触及财务类退市，交易所拟决定终止公司股票上市交易。 *ST嘉寓即将退市 4月25日晚，*ST嘉寓公告称，公司当天收到深交所《关于嘉寓控股股份公司股票终止上市的决定》，深交所决定终止公司股票上市。 该终止上市决定显示，*ST嘉寓在2025年3月4日至2025年3月31日期间，连续20个交易日的股票收盘价均低于1元，触及深交所《创业板股票上市规则(2024 年修订)》第10.2.1条第一款第二项规定的股票终止上市情形。根据深交所《创业板股票上市规则(2024年修订)》第10.2.5条的规定以及深交所上市审核委员 会的审议意见，决定公司股票终止上市。 由于公司股票因触及交易类强制退市情形被终止上市，公司股票将不进入退市整理期，将于交易所作出终止上市决定后十五个交易日内摘牌。 事实上，早在4月1日，*ST嘉寓就已经收到终止上市事先告知书，公司股票也自4 ...

Core Insights - Kangfang Biopharma announced the approval of its independently developed PD-1/VEGF bispecific antibody drug, Iwosimab (generic name: Iwosimab injection), for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) with PD-L1 positive (TPS≥1%) and negative EGFR mutations and ALK [1][2] - Iwosimab is the first drug to achieve significant positive results in a head-to-head Phase III clinical study against the leading drug, Pembrolizumab, providing a new, more efficient, and safer "chemotherapy-free" treatment option for first-line NSCLC [1] - The approval of Iwosimab for first-line treatment of PD-L1 positive NSCLC marks its second indication, allowing Chinese patients to access the world's best treatment options first [1] Clinical Recognition and Future Prospects - Iwosimab has gained widespread recognition among clinicians and patients for its efficacy in treating EGFR-TKI resistant NSCLC since its market launch nearly a year ago [2] - Recent Phase III studies comparing Iwosimab combined with chemotherapy against Tremelimumab combined with chemotherapy for first-line treatment of squamous NSCLC have also shown significant positive results, establishing Iwosimab as a new standard treatment [2] - Kangfang Biopharma's founder, Dr. Xia Yu, highlighted that Iwosimab has a forward-looking layout in multiple core tumor immunotherapy indications, with nearly 30 clinical studies underway, including Phase III and Phase II trials, covering nearly 20 indications, creating a leading advantage for its clinical and commercial value globally [2]

Group 1 - The core viewpoint of the article highlights that Nexperia is a trusted partner in the safety-critical motion control sector, both in China and globally, as stated by Robin Milavec, the company's President, CTO, and Chief Strategy Officer [2] - Nexperia is recognized as a leading company in motion control technology, providing innovative products and solutions for challenges in electrification, advanced driver-assistance systems (ADAS), autonomous driving, and shared mobility [2] - During the 21st Shanghai International Auto Show, Nexperia showcased its latest innovations in motion control, allowing visitors to experience next-generation breakthroughs in safety, comfort, and performance through simulated driving [2] Group 2 - The company collaborates closely with leading automotive manufacturers in China and globally, helping them to quickly respond to market trends and changes with high-quality, value-driven technologies [3] - The choice of Nexperia by automotive manufacturers is attributed to its foresight, speed, and value, which are crucial for success in a highly competitive and rapidly changing market [3]

登录新浪财经APP 搜索【信披】查看更多考评等级 □是 √否 一、主要财务数据 主要会计数据和财务指标 单位：元 币种：人民币 ■ 证券代码：600165 证券简称：*ST宁科（维权） 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 重要内容提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整，不存在虚假 记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务信息的真 实、准确、完整。 第一季度财务报表是否经审计 非经常性损益项目和金额 √适用 □不适用 单位：元 币种：人民币 ■ 对公司将《公开发行证券的公司信息披露解释性公告第1号一一非经常性损益》未列举的项目认定为非 经常性损益项目且金额重大的，以及将《公开发行证券的公司信息披露解释性公告第1号一一非经常性 损益》中列举的非经常性损益项目界定为经常性损益的项目，应说明原因。 □适用 √不适用 主要会计数据、财务指标发生变动的情况、原因 √适用 □不适用 ■ ...

Core Insights - The approval of the bispecific antibody drug Ivosidenib for the treatment of PD-L1 positive locally advanced or metastatic non-small cell lung cancer (NSCLC) is a significant milestone for the biopharmaceutical industry [2] - Ivosidenib's approval is based on positive results from the HARMONi-2 clinical trial, which demonstrated significant improvements in median progression-free survival (PFS) and overall survival (OS) [2] - Goldman Sachs predicts that if Ivosidenib succeeds in multiple indications, it could reshape the $90 billion immuno-oncology market, potentially making it the "new king of drugs" [3] Company Developments - Kangfang Biopharma's stock price has surged over 50% in the past month following the approval of Ivosidenib [3] - Summit Therapeutics, the U.S. partner of Kangfang Biopharma, saw its stock price plummet by over 36% after the approval announcement, raising concerns about the market's reaction [3] - The market speculates that the decline in Summit's stock may be due to investors shifting their focus to Kangfang Biopharma, which holds rights to Ivosidenib in China, allowing it to generate revenue sooner [3] Clinical Data Insights - Despite the favorable PFS data, the OS data does not show statistical significance, leading to concerns among investors regarding the drug's approval prospects in the U.S. [4] - The FDA considers OS as a critical endpoint for cancer treatment approval, while PFS is often used to assess the drug's efficacy in controlling tumor progression [4] - Analysts suggest that the OS curve data may not be available until later this year at a medical conference, with further interim analysis not expected until late 2025 or early 2026 [4]